These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11901091)

  • 21. Homology modeling and substrate binding study of human CYP2C9 enzyme.
    Payne VA; Chang YT; Loew GH
    Proteins; 1999 Nov; 37(2):176-90. PubMed ID: 10584064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
    Miners JO; Birkett DJ
    Br J Clin Pharmacol; 1998 Jun; 45(6):525-38. PubMed ID: 9663807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
    Mosher CM; Hummel MA; Tracy TS; Rettie AE
    Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
    Ridderström M; Masimirembwa C; Trump-Kallmeyer S; Ahlefelt M; Otter C; Andersson TB
    Biochem Biophys Res Commun; 2000 Apr; 270(3):983-7. PubMed ID: 10772937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
    Lewis DF; Dickins M; Weaver RJ; Eddershaw PJ; Goldfarb PS; Tarbit MH
    Xenobiotica; 1998 Mar; 28(3):235-68. PubMed ID: 9574814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling.
    Mancy A; Broto P; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1995 Aug; 34(33):10365-75. PubMed ID: 7654690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.
    Dickmann LJ; Rettie AE; Kneller MB; Kim RB; Wood AJ; Stein CM; Wilkinson GR; Schwarz UI
    Mol Pharmacol; 2001 Aug; 60(2):382-7. PubMed ID: 11455026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.
    Hutzler JM; Frye RF; Korzekwa KR; Branch RA; Huang SM; Tracy TS
    Eur J Pharm Sci; 2001 Aug; 14(1):47-52. PubMed ID: 11457649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity.
    Schwarz D; Kisselev P; Schunck WH; Chernogolov A; Boidol W; Cascorbi I; Roots I
    Pharmacogenetics; 2000 Aug; 10(6):519-30. PubMed ID: 10975606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
    Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.
    Kumar V; Wahlstrom JL; Rock DA; Warren CJ; Gorman LA; Tracy TS
    Drug Metab Dispos; 2006 Dec; 34(12):1966-75. PubMed ID: 16963489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.
    Gill HJ; Tjia JF; Kitteringham NR; Pirmohamed M; Back DJ; Park BK
    Pharmacogenetics; 1999 Feb; 9(1):43-53. PubMed ID: 10208642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
    Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
    Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
    Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
    Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.